Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Combating Obesity in a Workplace

NCT06768892 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-01-01
Last updated
2025-01-10

Condition(s) studied

Obesity and Obesity-related Medical Conditions

Investigational drug(s) / intervention(s)

Dietary InterventionCognitive Behavioral Therapy (CBT)Physical exercise training

Dietary Intervention: Each study participant will offer a tailored diet regimen according to age, sex, health status, physical activity and type of work either (office work or physical demanding work) after A 24-hour Dietary recall to calculate average calories requirements for each study participant separately. The participants' meals will be based on Mediterranean Diet and The Dietary Approaches to Stopping Hypertension (DASH Diet) as they proved effectiveness in lowering the risk of cardiovascular disease, insulin resistance, hypertension, obesity and Metabolic Syndrome. Dietary intervention aimed to the extent that 5-10% reduction in body weight, following the guideline of prevention and treatment of obesity.

Cognitive Behavioral Therapy (CBT): CBT method will be adapted and customized to facilitate a transition towards a heightened level of physical activity and to address the emotional and practical difficulties associated with weight loss. This encompassed assisting the participants in establishing attainable weight loss goals, identifying individualized approaches to manage appetite, sustaining healthy habits, and navigating social environments and circumstances related to food. The aforementioned factors were deliberated upon within the context of both group-based and individual settings, adhering to a meticulously customized guideline. This guideline encompassed the incorporation of positive thinking tactics, accompanied by assigned tasks to be completed between each session. The Cognitive Behavioral Therapy (CBT) intervention was administered as a 20-minute component within the weekly therapy sessions. cognitive-behavioral therapy (CBT) in conjunction with lif

Physical exercise training: A weekly session of physical exercise training lasting 10 to 20 minutes will be incorporated at the workplace. The primary objective of the sessions was to increase muscle mass in the lower limbs for the purpose of sustaining physical capacity and boosting quiescent metabolism. The exercises comprised squats involving one or two legs, performed with or without dumbbells and core balls, as well as lunges performed while strolling forward and to each side. Additional exercises that emphasized overall strength encompassed shoulder and arm movements, as well as abdominal and back extension exercises. Participants were encouraged to execute the strength training exercises depicted in the program's takeout pamphlets twice per week. Furthermore, participants will be motivated to engage in aerobic leisure activities for a duration of two hours per week, including bicycling, walking, running, swimming, or participating in various sports.

Study summary

Aim of the work: to assess the impact of 3-months workplace weight control program on both work ability and the severity of Metabolic Syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Manual workers and office employees * BMI of ≥25 kg/m2 , * History of repeated sick leaves from work related health problems especially (musculoskeletal disorders (MSDs) and obesity related comorbidities as hypertension, diseases of the heart, hyperlipidemia ,Diabetes Mellitus and Metabolic syndrome) * Age is above 18 years old Exclusion Criteria: * Age lower than 18 * BMI 24.9 and less

Primary outcome measure(s)

  • Change of severity of the Metabolic Syndrome components — 3 months
    The change in the severity of the metabolic syndrome components following 3-months obesity control intervention in comparison with the baseline. All participants were assessed for the five criteria of metabolic syndrome (according to IDF\&AHA): Metabolic syndrome was diagnosed if study Participants have at least three of the following five items: (1) Central obesity (waist circumference ≥ 102cm in male; ≥ 88 cm in female),(2) Blood pressure ≥130/85 mmhg,(3) Dyslipidemia (TG ≥ 150mg/dl), (4) Dyslipidemia (HDL-C \< 40mg/dl in male; \< 50mg/dl in female), and(5)Fasting blood glucose ≥ 110mg/dl. The blood pressure of participants in the office setting will be assessed and venous blood samples will be collected in order to assess blood lipids and fasting blood glucose levels. The safety blood profile will be conducted using established methodologies in a qualified laboratory specializing in clinical chemistry.

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06768892 on ClinicalTrials.gov ↗ ← All trials in Egypt